Six months ago, the Food and Drug Administration ordered 23andMe, the Google-backed genetic-testing startup, to stop selling saliva kits designed to deliver information about patients’ health. The results, the agency worried, weren’t accurate. The company is still selling the $99 home-test kits, but offering users only ancestry information and raw genetic data.
At a time when genetic testing is cheaper and faster than ever before, 23andMe has set off a national debate over how it and businesses like it should be regulated. The Chronicle caught up with CEO Anne Wojcicki last week at Stanford University, where she was attending the Big Data in Biomedicine Conference. This interview has been edited for clarity and brevity.
Share this article
Read the full, original story: Anne Wojcicki discusses future of 23andMe
